Preliminary clinical trial results have revealed that Tamarack Biotics’ TruActive MPC 85 ingredient has more than double the antibody response compared to a soy protein sample in individuals over the age of 60, the company said.
As people age, their immune systems tends to weaken in a condition described as immunosenescence, according to Tamarack Biotics.
“By the time you’re 70 only half the people benefit from a flu shot and the medical community knows this but they have not had a way of doing much about it,” Tamarack Biotics CEO, Bob Comstock, previously told DairyReporter.
The clinical trial looked at 50 elderly participants and their response to the tetanus vaccine in a double blind placebo controlled trial.
“We examined the effect of twice daily supplementation with 7.5 grams/serving of TruActive MPC 85 or a soy protein comparator,” the company said.
TruActive MPC 85 contains several immune active proteins that are protected from damage due to the company’s cold-processing technology. Immune active proteins have been linked to a range health including gastro-intestinal diseases protection, muscoskeletal beneficial benefits, antiviral properties, and immune system development.
Participants who received TruActive MPC 85 supplementation had a significantly higher antibody response to the tetanus vaccine (1,270%) compared to the those who received the soy protein supplementation (580%), suggesting that TruActive MPC 85 strengthens immunity in the elderly.
The results far exceeded Tamarack Biotics' expectations, Comstock said.
The company hopes that with the positive test results and its completion of GRAS review that it can eventually make its way into value-added, nutritional beverages.
“Along with our recently announced clinical trial results, this regulatory approval offers our customers the opportunity to safely launch sports nutrition and immune health products with proven health benefits,” Comstock added.